Rivals Cipla, Natco gain on Novartis drug patent rejection
Shares in Natco Pharma and Cipla gain after the Supreme Court dismissed Swiss drugmaker Novartis AG's petition seeking patent for its cancer drug Glivec.

Mumbai: Shares in Natco Pharma and Cipla gain after the Supreme Court dismissed Swiss drugmaker Novartis AG's petition seeking patent for its cancer drug Glivec.
[caption id="attachment_680976" align="alignleft" width="380"]
Analysts say that will be a big win for generic drugmakers. Reuters[/caption]
In a landmark judgment that has the potential to change the direction of India's pharmaceutical business, the Supreme Court said on Monday that the drug failed to qualify for a patent according to Indian law.
Analysts say that will be a big win for generic drugmakers given huge difference in prices of monopoly drugs, and as other emerging countries are also expected to follow he apex court's decision.
Cipla and Natco are already selling generic versions of Glivec in India. Natco was up 6 percent, while Cipla rose 2 percent at 2:25 pm
Reuters

BCCI earned more than Rs 2,400 crore in IPL 2022, reveal documents
Eight Russian judokas barred from world championships after Ukraine boycott
Old video of Donald Trump listening to Taylor Swift’s ‘Blank Space’ takes over internet; watch
SA20: Ex-New Zealand all-rounder Jacob Oram appointed MI Cape Town bowling coach
FIFA World Cup: Morgan Freeman, Jung Kook headline day one before Ecuador defeats hosts Qatar
